Compare Hims and Hers Health Inc (HIMS) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Global X SuperDividend ETF — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while Global X SuperDividend ETF trades at $23.96 (market cap $1.17B). The key difference: Hims and Hers Health Inc is far larger — about 5.6× Global X SuperDividend ETF's market cap, and Global X SuperDividend ETF is more actively traded (387,692 versus 14,842,814). Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Global X SuperDividend ETF for 47 Days on average.
| HIMS | SDIV | |
|---|---|---|
Market Cap | $6.55B | $1.17B |
Volume | 14,842,814 | 387,692 |
Sector | Health | Broad Market / Factor |
52-Week High | $62.76 | $26.34 |
52-Week Low | $14.52 | $22.90 |
Typical Hold Time | 21 Days | 47 Days |
Enterprise Value | $7.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.
The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.
SDIV trades at $23.96, up 1.61% with a bearish technical outlook from moving averages. The ETF maintains an 8%+ dividend yield but faces significant price erosion, having lost 66% since inception according to Seeking Alpha (2026-09-11). Recent institutional buying includes Ameritas Advisory Services increasing its position by 92.6% in Q2 2026. Technical indicators show mixed signals with neutral oscillators but bearish moving averages and ADX readings.
SDIV offers high income potential but carries substantial principal risk. The fund's deep value approach lacks quality screening, leading to persistent underperformance versus global benchmarks. While monthly dividends attract income seekers, the erosion of capital requires careful risk assessment for long-term investors considering this high-yield strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
